Medicenna Therapeutics Corp Stock Price, News & Analysis

Medicenna Therapeutics has presented updated clinical data from its ongoing Phase 1/2 ABILITY-1 study of MDNA11, a long-acting IL-2 super-agonist, at the 2025 AACR Annual Meeting. The study shows promising results both as monotherapy and in combination with KEYTRUDA:

• 10 patients achieved objective response (5 confirmed) in advanced/metastatic cancers resistant to immune checkpoint inhibitors
• 36% objective response rate (ORR) achieved in combination therapy
• 29.4% ORR achieved in monotherapy at ≥60 µg/kg dose
• Highest ORR of 50% observed in MSI-H patients and endometrial cancer patients

The treatment demonstrated an acceptable safety profile with over 90% of treatment-related adverse events being Grade 1-2 and transient. Two patients remain tumor-free and off-treatment after 2-3 years. Phase 2 combination dose expansion is now underway with MDNA11 at 90 µg/kg combined with KEYTRUDA.

Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company, has announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto. Dr. Fahar Merchant, President and CEO, will present on Monday, May 5, 2025, at 2:30 p.m. Eastern Time at the Metro Toronto Convention Centre.

The presentation will be accessible via webcast, with a 90-day replay available on Medicenna's Investor Relations website. This prestigious conference connects U.S., Canadian, and international investors with leading Canadian healthcare companies, facilitating corporate updates and one-on-one meetings.

Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company, has announced its participation in the upcoming Jones Healthcare and Technology Innovation Conference in Las Vegas. Dr. Fahar Merchant, President and CEO, will present on April 9, 2025, at 2:00 p.m. Pacific Time at The Venetian Resort.

The presentation will be accessible via webcast through Medicenna's Investor Relations website, with replay available for 90 days. The two-day conference, scheduled for April 8-9, 2025, will feature one-on-one meetings, presentations, fireside chats, panels, and networking opportunities, bringing together select innovative companies and institutional investors.

Medicenna Therapeutics (TSX: MDNA, OTCQX: MDNAF) has announced two upcoming poster presentations at the American Association for Cancer Research Annual Meeting 2025 (AACR 2025) in Chicago, Illinois, from April 25-30, 2025.

The first presentation will provide an update on the Phase 1/2 ABILITY-1 Study of MDNA11, their unique long-acting 'beta-enhanced not-alpha' interleukin-2 (IL-2) super-agonist. This poster will be presented on April 28, 2025, focusing on interim results in patients with advanced solid tumors.

The second presentation, scheduled for April 30, 2025, will showcase pre-clinical data for MDNA113, their novel first-in-class tumor-targeted and tumor-activated bi-functional anti-PD1-IL2 Superkine. Both posters will be made available on Medicenna's website after the conference concludes.

Medicenna Therapeutics (TSX: MDNA, OTCQX: MDNAF) presented new clinical data from the ABILITY-1 study of MDNA11 at the inaugural AACR Immuno-Oncology Conference. The study evaluates MDNA11 alone or combined with Merck's KEYTRUDA® in advanced solid tumors.

Key highlights include MDNA11's ability to significantly expand 'stem-like' CD8+ T cells, which are associated with more persistent anti-tumor activity. In the monotherapy dose expansion cohort, MDNA11 showed a 30% objective response rate in checkpoint-resistant patients. The combination with KEYTRUDA® demonstrated a 78% disease control rate, including one complete response, one partial response, and five stable disease cases.

The Safety Review Committee cleared the 120 µg/kg MDNA11 dose every two weeks in combination with KEYTRUDA®, with no dose-limiting toxicities observed. The company is also exploring dosing every three weeks for improved patient convenience. Additional tumor types will be evaluated, with combination dose expansion expected to begin mid-2025.

Medicenna Therapeutics (OTCQX: MDNAF) reported its Q3 FY2025 financial results and operational updates. Key highlights include a 78% disease control rate in the MDNA11-KEYTRUDA combination arm and a 30% objective response rate in the monotherapy dose expansion cohort. The company maintained a strong financial position with $30 million in cash, expected to fund operations through mid-2026.

The ABILITY-1 trial showed promising results, including one complete response in a 70-year-old patient with advanced anal cancer and one partial response in a colorectal cancer patient. R&D expenses increased to $3.4 million from $3.0 million year-over-year, while G&A expenses slightly decreased to $1.7 million. The company reported a quarterly net loss of $5.2 million ($0.07 per share).

Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company, has announced its participation in two major healthcare investor conferences in February 2025. The company will present at the Oppenheimer Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025, at 9:20 a.m. ET, with a webcast available for 180 days following the event.

Additionally, Medicenna will participate in a fireside chat at the B. Riley Securities Precision Oncology & Radiopharma Conference on Friday, February 28, 2025, in New York City. The company's management team will be available for one-on-one meetings with investors during both conferences. Interested investors can schedule meetings through conference representatives or by contacting Medicenna's investor relations team directly.

Medicenna Therapeutics (MDNAF) presented new preclinical data for MDNA11 at the 2024 San Antonio Breast Cancer Symposium. The data showed that single-agent MDNA11 outperformed combined immune checkpoint inhibitors in preventing metastasis and achieving long-term survival in triple negative breast cancer (TNBC) models.

Key findings demonstrated that a single low dose of MDNA11 as neoadjuvant therapy significantly prevented metastasis, with 6/7 mice at low-dose (2 mg/kg) and 7/8 mice at high-dose (5 mg/kg) surviving over 4 months without metastasis signs. The treatment also enabled memory immune response against tumor rechallenges, while promoting CD8+ T cell infiltration into the tumor microenvironment without affecting Treg cells.

Medicenna Therapeutics announced updated clinical data from its Phase 1/2 ABILITY-1 study, highlighting significant progress in cancer treatment. A notable achievement includes the first complete response (CR) in a 70-year-old patient with advanced anal cancer within 8 weeks of treatment combining MDNA11 with KEYTRUDA®.

The study demonstrates promising disease control rates of 55% in monotherapy and 78% in combination arms. Key findings include durable complete regression in two CPI-resistant patients, with one melanoma patient remaining tumor-free at week 63 and a pancreatic cancer patient maintaining response for 11 months post-study.

Safety profile shows over 90% of treatment-related adverse events were Grade 1-2 and transient. Additional clinical data will be presented at medical conferences in Q1 and Q2 of 2025.